Development and characterization of stabilized double loaded mPEG-PDLLA micelles for simultaneous delivery of paclitaxel and docetaxel

Drug Development and Industrial Pharmacy

Volumn 40, Issue 7, 2014, Pages 860-868

  Ouahab, Ammar ^a   Shao, Chengyi ^a,b   Shen, Yan ^a   Tu, Jiasheng ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Changzhou Qianhong Biopharm Co   (China)

Author keywords

Double loaded micelles; in vitro drug release; Micelle stability; Polymeric micelles; Taxanes

Indexed keywords

COPOLYMER; DOCETAXEL; DRUG VEHICLE; MONOMETHOXY POLY(ETHYLENE GLYCOL) BLOCK POLY( DEXTRO,LEVO LACTIDE); PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER; MACROGOL DERIVATIVE; METHOXY POLY(ETHYLENE GLYCOL)-POLY(LACTIDE); MICELLE; POLYESTER; TAXOID;

ARTICLE; CELL SIZE; DOUBLE DRUG LOADED MICELLE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; ENCAPSULATION; IN VITRO STUDY; MICELLE; PARTICLE SIZE; PROTON NUCLEAR MAGNETIC RESONANCE; SINGLE DRUG LOADED MICELLE; TRANSMISSION ELECTRON MICROSCOPY; CHEMISTRY; DRUG DESIGN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SOLUBILITY; SURFACE PROPERTY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DESIGN; DRUG LIBERATION; DRUG STABILITY; MAGNETIC RESONANCE SPECTROSCOPY; MICELLES; MICROSCOPY, ELECTRON, TRANSMISSION; PACLITAXEL; PARTICLE SIZE; POLYESTERS; POLYETHYLENE GLYCOLS; SOLUBILITY; SURFACE PROPERTIES; TAXOIDS;

EID: 84897538300     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2013.788017     Document Type: Article

References (40)

1. Tije AJt, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokin 2003;42: 665-85.
2. Weiss R, Donehower R, Wiernik P, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8: 1263-8.
3. Lorenz W, Reimann HJ, Schmal A, et al. Histamine release in dogs by Cremophor EL® and its derivatives: oxethylated oleic acid is the most effective constituent. J Inflamm Res 1977;7: 63-7.
4. Dye D, Watkins J. Suspected anaphylactic reaction to Cremophor EL. Brit Med J 1980;280:1353. (Pubitemid 10124276)
5. Zhang X, Jackson JK, Burt HM. Development of amphiphilic diblock copolymers as micellar carriers of taxol. Int J Pharma 1996; 132: 195-206.
6. Kim SC, Kim DW, Shim YH, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. Journal of Controlled Release 2001;72: 191-202.
7. Kim DW, Kim SY, Kim HK, et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced nonsmall- cell lung cancer. Ann Oncol 2007;18: 2009-14.
8. Lee KS, Chung HC, Im SA, et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 2008;108: 241-50.
9. Le GD, Gori S, Luo L, et al. Poly(N-vinylpyrrolidone)-blockpoly (D,L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation. J Control Release 2004;99: 83-101.
10. Liang HJ, Yang QX, Deng L, et al. Phospholipid-Tween 80 mixed micelles as an intravenous delivery carrier for paclitaxel. Drug Dev Ind Pharm 2011;37: 597-605.
11. Kim TY, Kim DW, Chung JY, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelleformulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004;10: 3708-16.
12. Lim WT, Tan EH, Toh CK, et al. Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors. Ann Oncol 2010;21: 382-8.
13. Lee SW, Chang DH, Shim MS, et al. Ionically fixed polymeric nanoparticles as a novel drug carrier. Pharm Res 2007;24: 1508-16.
14. Finley RS, Balmer C. Optimizing chemotherapy outcome. In: Finley RS, Balmer C, eds. Concepts in oncology therapeutics. Bethesda (MD): American Society of Health-System Pharmacists; 1998: 87-9.
15. Zhou Y, Feng L, Mueller T, et al. 17-AAG (KOS-953), an inhibitor of Hsp90 function, significantly enhances the cytotoxicity of anticancer drugs: an effective approach for combination therapy. AACR Meeting Abstracts 2004;2004:458-b.
16. Xiao L, Rasouli P, Ruden DM. Possible effects of early treatments of Hsp90 inhibitors on preventing the evolution of drug resistance to other anti-cancer drugs. Curr Medicinal Chem 2007;14: 223-32.
17. Min-Hyo S, Yil-woong Y, Jae-Won Y. Stable polymeric micelle-type drug composition and method for the preparation thereof. US Patent Application Publication 2003; Patent No. US2003/0143184 A1.
18. Shin HC, Alani AW, Rao DA, et al. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. J Control Release 2009;140: 294-300.
19. Sciencelab.com Inc. Pyrene; 2009. Available from: http://www.sciencelab. com/xMSDS-Pyrene-9924760 [last accessed 15 Dec 2012].
20. Knox C, Wishart D. Paclitaxel; 2009. Available from: http://www.drugbank. ca/drugs/DB01229 [last accessed 15 Dec 2012].
21. Knox C, Wishart D. Docetaxel; 2009. Available from: http://www.drugbank. ca/drugs/DB01248 [last accessed 15 Dec 2012].
22. Ouahab A, Shen Y, Tu JS. Novel oral delivery system of indomethacin by solidified mPEG-PDLLA micelles: in vivo study. Drug Deliv 2012;19: 232-7.
23. Cho YW, Lee J, Lee SC, et al. Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles. J Control Release 2004;97: 249-57.
24. Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006; 17: 1263-8.
25. Riley T, Stolnik S, Heald CR, et al. Physicochemical evaluation of nanoparticles assembled from poly(lactic acid)-poly(ethylene glycol) (PLA-PEG) block copolymers as drug delivery vehicles. Langmuir 2001;17: 3168-74.
26. Turro NJ, Kuo PL. Fluorescence probes for aqueous solutions of nonionic micelles. Langmuir 1985;1: 170-2.
27. Royal Society of Chemistry. Tanespimycin; 2007. Available from: http://www.chemspider.com/21106220 [last accessed 7 March 2013].
28. Hansch C, Hoekman D, Leo A, et al. Etoposide; 1995. Available from: http://www.drugbank.ca/drugs/DB00773 [last accessed 7 March 2013].
29. Hasenstein JR, Shin HC, Kasmerchak K, et al. Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG. Mol Cancer Ther 2012;11: 2233-42.
30. Straubinger RM, Balasubramanian SV. Preparation and characterization of taxane-containing liposomes. Methods Enzymol 2005; 391: 97-117.
31. Kim SC, Kim DW, Shim YH, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 2001;72: 191-202.
32. Dorr RT. Pharmacology of the taxanes. Pharmacotherapy 1997;17: 96S-104S. (Pubitemid 27411249)
33. Chimming R, Mason KA, Hunter N, et al. Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel. Cancer Chemother Pharmacol 1999;43: 165-72.
34. Berta O, Radka VCk, Vlasta D, et al. Effects of paclitaxel, docetaxel and their combinations on subcutaneous lymphomas in inbred Sprague-Dawley/Cub rats. Eur J Pharm Sci 2006;29: 442-50.
35. hrlichová M, Václavíkova R, Ojima I, et al. Transport and cytotoxicity of paclitaxel, docetaxel and three novel taxanes in human breast cancer cells N-S Arch. Pharmacol 2005;372: 95-105.
36. Izquierdo MA, Garcia M, Ponton JL, et al. A phase I clinical and pharmacokinetic study of paclitaxel and docetaxel given in combination in patients with solid tumours. Eur J Cancer 2006;42: 1789-96.
37. Lokich J. Phase I clinical trial of weekly combined paclitaxel plus docetaxel in patients with solid tumors. Cancer 2000;89: 2309-14.
38. Van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 2001;19: 125-41.
39. Majeti NV, Ravi K, Neeraj K. Polymeric controlled drug-delivery systems: perspective issues and opportunities. Drug Dev Ind Pharm 2001;27: 1-30.
40. Ki YC, Kyung HM, Hong YY, et al. PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo. Biomaterials 2011;32: 1880-9.